Development of Metal-Based Drugs and Application in Clinical Treatment

被引：1
作者：
Shao, Yi Ming [1 ,4 ]
Sharavyn, Bold [2 ]
Huang, Ping [3 ]
Naranmandura, Hua [1 ,4 ,5 ]
Wang, Qian Qian [4 ,5 ]
机构：
[1] Inner Mongolia Med Univ, Coll Pharmaceut Sci, Hohhot, Peoples R China
[2] Mongolian Natl Univ Med Sci, Dept Pharmacol, Ulan Bator, Mongolia
[3] Zhejiang Prov Peoples Hosp, Dept Pharm, Hangzhou, Peoples R China
[4] Zhejiang Univ, Dept Pharmacol, Sch Med, Hangzhou 310058, Peoples R China
[5] Zhejiang Univ, Sch Med & Publ Hlth, Dept Hematol & Oncol, Hangzhou 310058, Peoples R China
来源：
NATURAL PRODUCTS JOURNAL | 2022年 / 12卷 / 03期
基金：
中国国家自然科学基金; 中国博士后科学基金;
关键词：
Metals; cancer; selenium; platinum; arsenic; antimony; APL; SELENIUM; THERAPY; CANCER; LEISHMANIASIS; METABOLISM; PREVENTION; RESISTANCE; ANTIMONY;
D O I：
10.2174/2210315511666210512025010
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Metals occur naturally in soil and many kinds of rocks, particularly in minerals and ores, which also play a vital role in living systems such as plants and animals. Over the large time scale, metal evolution from toxins to drugs has achieved a milestone mean in medicine. Currently, a few metal-based drugs (i.e., metallodrugs) have been used in the clinic to treat patients with different medical conditions, making exciting new developments in anticancer therapeutics (e.g., arsenic trioxide and cisplatin) that quickly move into focus. Moreover, a thorough understanding of the properties and effects of metals on the human body could improve the development and innovation of metal-based drugs. In this review, we have comprehensively described the discovery and development of metal-based anticancer drugs, as well as their side effects in clinical treatment. Although metallodrugs have shown promising outcomes in the treatment of cancers, further investigation is needed to optimize their side effect for broader applications.
引用
收藏
页码：13 / 19
页数：7
相关论文
共 79 条
[51]   Inorganic arsenic and its methylated metabolites as endocrine disruptors in the placenta: Mechanisms underpinning glucocorticoid receptor (GR) pathway perturbations [J].
Meakin, Cassandra J. ;
Szilagyi, John T. ;
Avula, Vennela ;
Fry, Rebecca C. .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 409
[52]   Atypical presentations of cutaneous leishmaniasis: A systematic review [J].
Meireles, Camilla Barros ;
Maia, Lais Chaves ;
Soares, Gustavo Coelho ;
Pinheiro Teodoro, Ilara Parente ;
Vieira Gadelha, Maria do Socorro ;
Lima da Silva, Claudio Gleidiston ;
Pereira de Lima, Marcos Antonio .
ACTA TROPICA, 2017, 172 :240-254
[53]  
Mendola Diego La, 2016, Curr Top Med Chem, V16, P3381
[54]   Metal complexes in cancer therapy - an update from drug design perspective [J].
Ndagi, Umar ;
Mhlongo, Ndumiso ;
Soliman, Mahmoud E. .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 :599-616
[55]   Cisplatin induced Mitochondrial DNA damage in dorsal root ganglion neurons [J].
Podratz, Jewel L. ;
Knight, Andrew M. ;
Ta, Lauren E. ;
Staff, Nathan P. ;
Gass, Jennifer M. ;
Genelin, Konstantin ;
Schlattau, Alexander ;
Lathroum, Liselle ;
Windebank, Anthony J. .
NEUROBIOLOGY OF DISEASE, 2011, 41 (03) :661-668
[56]   Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives [J].
Pujade-Lauraine, Eric ;
Banerjee, Susana ;
Pignata, Sandro .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27) :2437-+
[57]   Advances in Toxicological Research of the Anticancer Drug Cisplatin [J].
Qi, Luyu ;
Luo, Qun ;
Zhang, Yanyan ;
Jia, Feifei ;
Zhao, Yao ;
Wang, Fuyi .
CHEMICAL RESEARCH IN TOXICOLOGY, 2019, 32 (08) :1469-1486
[58]   Unexpected therapeutic effects of cisplatin [J].
Raudenska, Martina ;
Balvan, Jan ;
Fojtu, Michaela ;
Gumulec, Jaromir ;
Masarik, Michal .
METALLOMICS, 2019, 11 (07) :1182-1199
[59]   Selenium and human health [J].
Rayman, Margaret P. .
LANCET, 2012, 379 (9822) :1256-1268
[60]   The rediscovery of platinum-based cancer therapy [J].
Rottenberg, Sven ;
Disler, Carmen ;
Perego, Paola .
NATURE REVIEWS CANCER, 2021, 21 (01) :37-50
12345678